Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

Merck's Q2 Sales Hit $16.6 Billion as Oncology and Animal Health Drive Growth

Guavy AI Editorial Team
Instruments
MRK
Share

Merck's Q2 2026 financial results show continued strength in oncology and animal health, as well as increasing contributions from new product launches.

The company reported worldwide sales of $16.6 billion for the quarter, with CEO Rob Davis attributing the success to 'strong execution' and growing contributions from new products.

Davis also highlighted the FDA approval of LIPFENDRA as a major achievement for the company and its patients.

More on Stocks

Stocks just now

FAA Certifies Boeing 737 MAX-7 After Decade-Long Review

Stocks just now

AI-Driven Earnings Lift S&P 500 to Record Highs

Stocks just now

Boeing's Smallest 737 Max Jet Cleared for Take-Off After Years of Delays

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Real-time market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy